Adverse drug reactions (n≥30) |
Achiral |
Achiral |
Chiral mixture |
Chiral mixture |
Pure enantiomer |
Pure enantiomer |
Total |
Total |
p-value |
|
Mean |
± SD |
Mean |
± SD |
Mean |
± SD |
Mean |
± SD |
|
Hepatotoxicity (n=79), yrs. |
19.1 |
± 25.8 |
13.8 |
± 12.7 |
12.3 |
±
19.6 |
17.2 |
± 22.6 |
0.550 |
Cardiovascular (n=60), yrs. |
17.7 |
± 27.4 |
23.2 |
± 14.4 |
35.9 |
±
31.6 |
23.8 |
± 24.7 |
0.034* |
Drug abuse (n=51), yrs. |
31.9 |
± 33.0 |
31.5 |
± 16.7 |
45.1 |
± 36.0 |
35.1 |
± 28.1 |
0.162 |
Neurological (n=50), yrs. |
28.9 |
± 27.6 |
18.8 |
± 18.6 |
53.3 |
±
62.3 |
32.5 |
± 38.8 |
0.234 |
Haematological (n=49), yrs. |
38.4 |
± 31.5 |
16.1 |
± 13.3 |
20.0 |
±
18.6 |
30.7 |
± 28.2 |
0.061 |
Carcinogenicity (n=44), yrs. |
39.2 |
± 40.5 |
17.9 |
± 21.4 |
11.7 |
±
6.3 |
30.2 |
± 38.6 |
0.093 |
Dermatological (n=38), yrs. |
28.4 |
± 20.4 |
9.3 |
± 10.9 |
18.0 |
±
14.1 |
23.4 |
± 19.8 |
0.018† |
Immunological (n=30), yrs. |
38.1 |
± 29.4 |
15.1 |
± 13.9 |
21.3 |
±
15.9 |
28.0 |
± 25.0 |
0.075 |